New CEO Plans ‘Transformation’ For Jubilant Generics
Follows A Poor Q1 And Further FDA Observations After Roorkee Import Alert
Executive Summary
Jubilant Pharmova is planning to transform its generics business with the appointment of a new managing director and CEO, after a difficult period for the unit that saw a tough Q1 amid ongoing difficulties linked to an import alert for its Roorkee manufacturing plant.